Ceribell (CBLL) Debt to Equity (2024 - 2026)

Ceribell (CBLL) reported Debt to Equity of $0.14 for Q1 2026, up 30.41% on a YoY basis from $0.11 in Q1 2025, and up 10.9% quarter-over-quarter from $0.13 in Q4 2025.

Ceribell (CBLL) Debt to Equity (2024 - 2026) Analysis & Trends

Ceribell has reported Debt to Equity for 3 years, with the latest figure at $0.14 in Q1 2026.

  • For the quarter ending Q1 2026, Debt to Equity rose 30.41% year-over-year to $0.14; the trailing twelve-month figure through Mar 2026 stood at $0.14 (up 30.41% YoY), and the FY2025 full-year result was $0.13, up 24.66% from the prior year.
  • Debt to Equity for Q1 2026 stood at $0.14, up from $0.13 in the prior quarter.
  • The five-year high for Debt to Equity was $0.14 in Q1 2026, with the low at -$0.14 in Q3 2024.
  • Historically, Debt to Equity has averaged $0.08 across 3 years, with a median of $0.11 in 2025.
  • The largest YoY upside for Debt to Equity was 183.93% in 2025 against a maximum downside of 24.66% in 2025.
  • Ceribell's Debt to Equity stood at $0.1 in 2024, then gained by 24.66% to $0.13 in 2025, then climbed by 10.9% to $0.14 in 2026.
  • The last three Debt to Equity figures came in at $0.14 (Q1 2026), $0.13 (Q4 2025), and $0.12 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 152.92 Bn 146.27 Bn 6.27 Bn 0.65
2 Stryker 119.50 Bn 116.62 Bn 3.81 Bn 0.64
3 Medtronic 102.71 Bn 94.54 Bn 5.76 Bn 0.57
4 Boston Scientific 69.72 Bn 68.51 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 49.24 Bn 45.57 Bn 1.29 Bn 0.06
6 GE HealthCare Technologies 29.74 Bn 27.67 Bn 1.98 Bn 0.95
7 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 0.71
8 Dexcom 28.96 Bn 27.84 Bn 750.30 Mn -
9 Steris 20.31 Bn 19.88 Bn 697.10 Mn 0.27
10 Ceribell 695.83 Mn 554.65 Mn 23.12 Mn 0.14

Historic Data

Download Data
DateValue
Mar 31, 2026 0.14
Dec 31, 2025 0.13
Sep 30, 2025 0.12
Jun 30, 2025 0.11
Mar 31, 2025 0.11
Dec 31, 2024 0.10
Sep 30, 2024 -0.14